Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

6.03
Delayed Data
As of Apr 24
 -0.375 / -5.85%
Today’s Change
3.10
Today|||52-Week Range
7.84
-20.24%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$419.9M

Company Description

Progenics Pharmaceuticals, Inc. engages in developing medicines for oncology. It offers clinical trials of product candidates for prostate cancer, and resumed a pivotal trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in Tarrytown, NY.

Contact Information

Progenics Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown New York 10591
P:(914) 789-2800
Investor Relations:

Employees

Shareholders

Mutual fund holders48.70%
Other institutional40.25%
Individual stakeholders15.25%

Top Executives

Mark Robert BakerPresident, Chief Executive Officer & Director
Angelo William LovalloCFO, Treasurer, Principal Accounting Officer & VP
Robert J. IsraelExecutive Vice President-Medical Affairs
John W. BabichSenior Vice President
Nitya G. RaySenior Vice President-Manufacturing

To view my watchlist

Not a member yet?

Sign up now for a free account